T. Rowe Price Associates
PRLD icon

T. Rowe Price Associates’s Prelude Therapeutics PRLD Stock Holding History

T. Rowe Price Associates’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-755,956
Closed -$2.19M – 3182
2025
Q4 		$2.19M Sell
755,956
-120,382
-14% -$203K ﹤0.01% 1707
2025
Q3 		$1.26M Sell
876,338
-51,270
-6% -$51.4K ﹤0.01% 1957
2025
Q2 		$743K Sell
927,608
-48,539
-5% -$42K ﹤0.01% 2116
2025
Q1 		$750K Sell
976,147
-53,052
-5% -$49.5K ﹤0.01% 2087
2024
Q4 		$1.31M Sell
1,029,199
-68,400
-6% -$90.8K ﹤0.01% 1854
2024
Q3 		$2.27M Buy
1,097,599
+206,301
+23% +$955K ﹤0.01% 1573
2024
Q2 		$3.4M Sell
891,298
-50,673
-5% -$206K ﹤0.01% 1356
2024
Q1 		$4.47M Sell
941,971
-100,766
-10% -$392K ﹤0.01% 1246
2023
Q4 		$4.45M Sell
1,042,737
-24,121
-2% -$73.4K ﹤0.01% 1237
2023
Q3 		$3.3M Sell
1,066,858
-15,390
-1% -$57.7K ﹤0.01% 1297
2023
Q2 		$4.87M Buy
1,082,248
+797,886
+281% +$4.77M ﹤0.01% 1194
2023
Q1 		$1.62M Sell
284,362
-16,315
-5% -$99.5K ﹤0.01% 1547
2022
Q4 		$1.82M Sell
300,677
-12,488
-4% -$80K ﹤0.01% 1507
2022
Q3 		$2.07M Buy
313,165
+5,812
+2% +$39.2K ﹤0.01% 1441
2022
Q2 		$1.6M Sell
307,353
-15,635
-5% -$79.6K ﹤0.01% 1696
2022
Q1 		$2.23M Buy
322,988
+18,656
+6% +$171K ﹤0.01% 1656
2021
Q4 		$3.79M Sell
304,332
-90,944
-23% -$1.48M ﹤0.01% 1540
2021
Q3 		$12.4M Sell
395,276
-5,526
-1% -$179K ﹤0.01% 1401
2021
Q2 		$11.5M Sell
400,802
-22,189
-5% -$790K ﹤0.01% 1401
2021
Q1 		$18.3M Buy
422,991
+35,311
+9% +$2.34M ﹤0.01% 1294
2020
Q4 		$27.7M Sell
387,680
-12,320
-3% -$613K ﹤0.01% 1132
2020
Q3 		$12.1M Buy
+400,000
New +$11.3M ﹤0.01% 1256

Other funds holding PRLD

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

T. Rowe Price Associates's PRLD Position: Q1 2026 in Review

T. Rowe Price Associates sold out of Prelude Therapeutics (PRLD) in Q1 2026, closing a stake of 755,956 shares — an estimated $2.19M sold.

T. Rowe Price Associates first reported a position in PRLD in Q3 2020 and held it in 22 quarters. The position peaked at $27.7M in Q4 2020. 55 funds tracked by Wall St. Rank hold PRLD as of Q1 2026.

  • T. Rowe Price Associates reported no remaining Prelude Therapeutics position as of Q1 2026 after selling out during the quarter.
  • T. Rowe Price Associates sold 755,956 Prelude Therapeutics shares in Q1 2026, an estimated $2.19M.
  • T. Rowe Price Associates first reported a position in Prelude Therapeutics in Q3 2020 and held it in 22 quarters.
  • T. Rowe Price Associates's Prelude Therapeutics position peaked at $27.7M in Q4 2020.
  • 55 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.